Study Shows Relation of LDL Cholesterol Levels and PCI Outcomes
September 14, 2020—The American College of Cardiology (ACC) reported new findings indicating that levels of low-density lipoprotein cholesterol (LDL-C) after coronary revascularization with percutaneous coronary intervention (PCI) were strongly associated with the subsequent incidence of major adverse cardiovascular events (MACE).
First Patient Enrolled in TRANSFORM-1 RCT of Concept Medical’s MagicTouch Sirolimus-Coated Balloon for Small Coronary Vessels
September 2, 2020—Concept Medical Inc. announced the enrollment of the first patient in the TRANSFORM-1 randomized clinical trial (RCT) of the treatment of small coronary vessels with percutaneous coronary intervention (PCI) using the company’s MagicTouch sirolimus-coated balloon.
Impact of Angina Drug Trimetazidine Evaluated After Successful PCI Revascularization
August 30, 2020—Trimetazidine administered after a successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, concluded investigators in the ATPCI trial, which was sponsored by I.R.I.S., Institut de Recherches Internationales Servier based in Suresnes, France.
ACC’s MedAxiom 2020 Compensation and Production Survey Includes New PCI Measures
August 27, 2020—MedAxiom, an American College of Cardiology company focused on cardiovascular organizational performance solutions, has released its eighth annual Cardiovascular Provider Compensation and Production Survey.
Study From China Evaluates Prognosis for STEMI Patients During COVID-19 Pandemic
August 19, 2020—The American College of Cardiology (ACC) announced the publication of a study showing that the risk of in-hospital death and in-hospital heart failure increased for patients with ST-segment elevation myocardial infarction (STEMI) in China during the COVID-19 pandemic.
Italian Study Evaluates Changes in Hospital Admissions for STEMI Caused by COVID-19 Pandemic
August 14, 2020—Preliminary results from a cardiovascular regional public service health care hub in Italy demonstrated a significantly longer time from symptoms onset to hospital admission among patients with ST-segment elevation myocardial infarction (STEMI) during the COVID-19 pandemic compared with the same time period in the previous 2 years.
First Patient Enrolled in REFORM Trial of Biosensors’ Biolimus A9 DCB to Support CE Mark Approval
August 13, 2020—Biosensors International Group, Ltd. announced the enrollment of the first patient in the prospective, randomized, noninferiority REFORM trial, which aims to determine the safety and efficacy of the company’s Biolimus A9 drug-coated balloon (DCB) for the treatment of in-stent restenosis.
Survival Rates With Abiomed's Impella Heart Pump Evaluated in Japanese Registry
July 30, 2020—Abiomed announced that a 3-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump showed that use of the device is associated with a 77% survival rate at 30 days in acute myocardial infarction (AMI) cardiogenic shock patients.
Study Evaluates Association of Readmissions After NSTEMI and Index Coronary Revascularizations
July 20, 2020—A study of the rate, causes, and predictors of 90‐day readmissions and the association with index hospitalization coronary revascularization after non–ST-segment elevation myocardial infarction (NSTEMI) in the United States was published by Jayakumar Sreenivasan, MD, et al online ahead of print in Catheterization & Cardiovascular Interventions.
Canon Medical Introduces New Configuration of Aquilion One/Genesis Edition Cardiac CT Solution
July 17, 2020—Canon Medical Systems USA, Inc. announced the introduction of a new configuration of the Aquilion One/Genesis Edition, an artificial intelligence–powered wide-area CT system for structural and coronary imaging.
One-Year Follow-Up Completed in PIONEER-III Trial of Sinomed’s Buma Supreme DES
July 13, 2020—Sino Medical Science Technology Inc. (Sinomed), a Tianjin, China–based developer of neuro- and cardiovascular technologies, announced the completion of 1-year follow-up in the randomized global PIONEER-III trial evaluating the Buma Supreme coronary drug-eluting stent (DES).
Acist Launches Navvus II Rapid Exchange FFR Microcatheter
July 9, 2020—Acist Medical Systems, Inc., a Bracco Group Company, announced the global launch of the Navvus II rapid exchange fractional flow reserve (FFR) microcatheter, a second-generation device for use with the company's RXi rapid exchange FFR system in percutaneous coronary intervention (PCI) procedures.
Study Examines Racial Disparities in PCI Outcomes
July 6, 2020—The American College of Cardiology (ACC) announced the publication of a study showing that Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major adverse outcomes, including death, compared with White patients.
Sponsored by Abiomed, Inc.
May/June 2020 Supplement
Sponsored by Abiomed, Inc.
May/June 2020 Supplement
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in Europe.